United States RE44,040: What Is It Covering in Claims and the Practical Patent Landscape?
US RE44,040 (reissue) asserts claim scope around benzonnaphthalene (benzonaphthalene) compounds used in two tracks:
1) Methods for treating dermatologic, rheumatismal, respiratory, or ophthalmologic diseases by administering a defined benzonaphthalene compound.
2) Cosmetic and hair-hygiene compositions containing the same benzonaphthalene compound classes, with specified concentration ranges in dependent claims.
The reissue claims you provided are broad in chemical definition and disease framing, with narrower restrictions in the cosmetic embodiments (notably concentration windows in claims 3 and 4).
What Do the Independent Claims Actually Cover? (Claim 1 vs Claim 2)
1) Claim 1: Treatment method using a specified benzonaphthalene class
Claim 1 is a process/method-of-use claim. It requires:
- A person suffering from a listed disease category:
dermatologic, rheumatismal, respiratory or ophthalmologic.
- Administration of an effective amount of a composition.
- The composition contains, in a pharmaceutically acceptable vehicle, as active ingredient:
- a benzonaphthalene compound of formula (as shown in the claim) defined by substituent variables R1, R2, R3, R4, R5, R6, R7 (and R’/R”), including salt forms.
Key structural logic in the claim language:
- R1 is defined by one of two options:
- (i) one substituent defined by the claim’s first depicted group, or
- (ii) –CH2OH.
- R6 is defined by one of two options:
- (i) one substituent defined by the claim’s first depicted group, or
- (ii) OR7, where R7 is selected from:
- hydrogen
- alkyl C1-20
- monohydroxyalkyl or polyhydroxyalkyl
- or R’ and R” define additional substituted motifs that can include:
- hydrogen, lower alkyl
- mono/polyhydroxyalkyl
- aryl
- a residue of an amino acid or carbohydrate residues including:
- glucosamine, galactosamine, or mannosamine
- or together form a heterocycle selected from:
- piperidino, piperazino, morpholino, pyrrolidino
- R2:
- hydrogen
- branched/straight chain alkyl C1-15
- alkoxy C1-4
- cycloaliphatic radical
- R3:
- hydrogen
- hydroxy
- branched/straight chain alkyl C1-4
- alkoxy C1-10
- cycloaliphatic radical among:
- 1-methylcyclohexyl
- 1-adamantyl
- thiocycloaliphatic radical
- or –O–Si(CH3)2–R8 with R8 linear/branched alkyl
- R4 and R5 independently:
- hydrogen
- lower alkyl
- hydroxy
- lower acyloxy
- or salt thereof
Net effect: Claim 1 covers a large family of benzonaphthalene substituted with multiple allowable groups, including glycomimetic residues (glucosamine/galactosamine/mannosamine) and heterocycles, plus silylether-type motifs via –O–Si(CH3)2–R8.
2) Claim 2: Cosmetic composition for skin and hair hygiene
Claim 2 is also a formulation/composition claim, but it is limited to cosmetic use:
- A cosmetically acceptable vehicle plus effective amount of:
- at least one benzonaphthalene compound of the same general formula family.
- The substituent sets for R1, R6, R2, R3, R4/R5 are the same structural conceptually, with one important simplification:
- Claim 2’s variable definitions for R2 and R3 do not include some of the extra options shown in claim 1 (for example, claim 2 text as provided omits some detailed R6/R7 sub-clauses that claim 1 includes; the overall scope remains broad).
- Claim 2 is explicitly for “both and hair hygiene” (as written in the claim text you provided, i.e., skin and hair use).
Net effect: Claim 2 targets the same benzonaphthalene chemical class, but only as a cosmetic/hygiene active, not as a drug therapy.
What Narrowing Happens in Dependent Claims? (Claims 3 and 4)
3) Claim 3: Cosmetic active concentration 0.0005 to 2 wt%
Claim 3 limits the active ingredient to:
- 0.0005 to 2 weight percent
based on total composition weight.
4) Claim 4: Cosmetic active concentration 0.01 to 1 wt%
Claim 4 limits the active ingredient to:
- 0.01 to 1 weight percent.
Practical reading: Claim 4 is narrower and sits inside Claim 3’s band. A product matching Claim 4 automatically matches Claim 3 (assuming no other constraints apply).
Where the Scope Likely Expands vs Contracts (Based on Claim Language Alone)
Likely scope expanders
- Broad disease categories in Claim 1
The method covers multiple therapeutic areas with no specific indication names.
- Broad substituent combinatorics
R1–R6 options and multiple alternative substituents mean the claim is not limited to one compound.
- Inclusion of salt forms
“or a salt thereof” adds coverage for counterion variants.
- “At least one” active ingredient in Claim 2
Allows combination formulations while still infringing.
Likely scope restrainers
- Chemical formula tethering
Infringement requires a benzonaphthalene compound that matches the enumerated R-group scheme.
- Cosmetic-specific concentration limits in dependent claims
Claim 3 and 4 constrain wt%.
What Does This Mean for Freedom-to-Operate? (Claim-by-Claim Risk Mapping)
Method-of-use risk (Claim 1)
A competitor’s product or pipeline is most exposed when:
- the active is a benzonaphthalene within the enumerated formula family, and
- the company markets or uses it for dermatologic/rheumatismal/respiratory/ophthalmologic disease treatment by administering an effective amount.
Even if formulation resembles a cosmetic, Claim 1 can still be implicated if the use is therapeutic and the active matches the formula.
Cosmetic formulation risk (Claims 2-4)
Cosmetic products face a dual exposure:
- structural match to the benzonaphthalene formula, and
- for claims 3 and 4, being inside the relevant wt% windows:
- 0.0005 to 2 wt% (Claim 3)
- 0.01 to 1 wt% (Claim 4)
A cosmetic using the same compound class but outside those ranges may avoid dependent claims while still potentially implicating Claim 2 (unless Claim 2 is interpreted to require “effective amount” but without strict wt% boundaries).
Patent Landscape: What a RE44,040-anchored Portfolio Typically Looks Like
A reissue patent generally follows an earlier issued patent (the “original”), often carrying:
- continuity in chemical structure coverage, and
- refinements to claim language and/or correction of errors, and sometimes
- reshaping of the claim set while retaining priority to earlier disclosures.
Given only the claim text you supplied, the firmest landscape conclusions that can be stated without additional bibliographic or cited-document data are limited to claim-structure positioning:
1) Chemical-entity anchored claims
This reissue claim set is not limited to a single benzonaphthalene. It is a structure-variable family claim. That is characteristic of portfolios that also include:
- multiple examples in the specification,
- dependent sub-claims in the original filing (not provided here),
- and likely earlier priority filings covering related benzonaphthalene substitution patterns.
2) Dual-use strategy (drug + cosmetic/hair hygiene)
The portfolio footprint is likely designed to capture:
- therapeutic administration (Claim 1), and
- consumer product adoption (Claim 2-4).
This pattern is often used to keep protection active across different regulatory lanes.
3) Coverage that withstands “analog” design-arounds
Because the formula includes a wide set of permitted R-groups, design-around strategies relying on small changes can fail unless:
- the altered substituent falls outside enumerated options, or
- the compound ceases to be a benzonaphthalene “of the formula” under claim construction.
Key Competitive “Non-Infringement” Levers (Conceptual, Claim-Language Based)
A competitor would typically attempt one of these, if they are feasible:
- Substituent mismatch: choose an alternative substituent pattern not allowed for any of R1, R2, R3, R4, R5, R6, R7, R’/R”.
- Use mismatch: avoid therapeutic disease treatment claims in the categories listed in Claim 1; keep the use cosmetic only (or avoid “administering… an effective amount” for those disease categories).
- Cosmetic concentration mismatch: if the compound is otherwise within the formula, place active % outside the dependent bands (Claim 3 and Claim 4). Claim 2 may still remain a risk if “effective amount” is met and the formula matches.
What to Watch in Prosecution/Validity (Only From Claim Text)
The claim text is heavily variable and includes multiple alternative moieties, including carbohydrate residues and heterocycles, plus silicon-based substituents. Two validity pressure points commonly arise in this style of claim drafting:
- Enablement/definiteness at the edges of the variable scope (the broader the permitted substitutions, the more the spec must support them).
- Written description adequacy for the full breadth of enumerated R-group combinations.
These are not conclusions about this particular patent’s validity, but they are the typical pressure points for formula-variable family reissues.
Key Takeaways
- RE44,040 claim scope is a benzonaphthalene compound family defined by a variable substitution scheme over R1-R7 (and R’/R” for certain sub-motifs), plus salt forms.
- Claim 1 covers therapeutic administration for dermatologic, rheumatismal, respiratory, or ophthalmologic diseases using an effective amount in a pharmaceutically acceptable vehicle.
- Claim 2 covers cosmetic and hair-hygiene compositions using the same benzonaphthalene family as active.
- Claims 3 and 4 narrow cosmetic exposure by wt% windows:
- 0.0005 to 2 wt% (Claim 3)
- 0.01 to 1 wt% (Claim 4)
- The overall structure-variable format creates high analog coverage and makes design-around hinge on substituent selection outside enumerated options or use/regulatory category and concentration avoidance.
FAQs
-
Does RE44,040 protect a single compound or many?
It protects a family of benzonaphthalene compounds defined by variable R-group selections plus salts.
-
Is the patent about drugs, cosmetics, or both?
Both. Claim 1 is therapeutic use across multiple disease categories; Claim 2 is cosmetic and hair hygiene use.
-
What cosmetic dosage ranges are explicitly claimed?
Claim 3: 0.0005 to 2 wt%. Claim 4: 0.01 to 1 wt%.
-
Can a cosmetic still infringe even if it avoids the wt% bands?
It may still implicate Claim 2 if the active matches the formula and is used in an “effective amount,” but Claims 3 and 4 depend on the stated wt% ranges.
-
What is the main freedom-to-operate risk driver for this claim set?
Whether the candidate compound matches the benzonaphthalene formula constraints and whether it is used as claimed (therapeutic disease treatment for Claim 1, cosmetic/hair hygiene for Claim 2).
References
[1] United States Reissue Patent RE44,040 (claim text as provided by user).
